Health Condition 1: null- Schizophrenia - Paranoid
Conditions
Interventions
Intervention1: Tab. Olanzapine: Tab. Olanzapine in dosages of 5 - 20 mg/day
Duration of trial 6 months.
Control Intervention1: Haloperidol: Tab. Haloperidol in doses of 5 - 20 mg/day.
Duration of tria
Sponsors
Government Medical College and Hospital
Eligibility
Inclusion criteria
Inclusion criteria: Diagnosis of paranoid schizophrenia according to ICD-10 Attending the outpatient clinic or those admitted to the inpatient services Patients in the age group of 18 to 65 years Patients having normal intelligence Patients who were willing to give written informed consent were included. Patients should have been drug naïve for at least 2 weeks prior to the baseline assessments.
Exclusion criteria
Exclusion criteria: Patients with past history of poor response or hypersensitivity to olanzapine or haloperidol were excluded. We also excluded patients with co-morbid substance related disorders except nicotine and caffeine Patients with chronic medical illness, neurological disorders, head injury, tumors, movement disorder, pregnant and lactating females. Any other condition which affected the quality of life of the patients was an exclusion criterion. Patients who were unwilling to participate in the study were also excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Score on Positive and negative syndrome scale for schizophrenia 2. Score on WHO QoL Bref Hindi. 3. Side effects like extrapyramidal symptoms, metabolic parameters, sexual side effectsTimepoint: 1. Score on Positive and negative syndrome scale for schizophrenia 2. Score on WHO QoL Bref Hindi. 3. Side effects like extrapyramidal symptoms, metabolic parameters, sexual side effects | — |
Secondary
| Measure | Time frame |
|---|---|
| serum electrolytes QTc intervalTimepoint: baseline 1 month 3 months 6 months | — |
Countries
India
Contacts
Public ContactBir Singh Chavan
Government Medical College and Hospital, Chandigarh
Outcome results
None listed